Cidara touts 'pos­i­tive' PhII tri­al da­ta for an­ti­fun­gal, shares yo-yo on the news

This time last year, Cidara $CDTX was re­port­ing a flop in the clin­ic for its lead drug, an an­ti­fun­gal that failed to im­press in Phase II tri­als. Now, af­ter scrap­ping its old plan re­tool­ing a lead pro­gram, it’s got hap­pi­er Phase II news.

The San Diego com­pa­ny re­port­ed Mon­day morn­ing that its lead an­ti­fun­gal drug can­di­date, called Reza­fun­gin, met all its pri­ma­ry ob­jec­tives in a Phase II tri­al test­ing its IV pro­gram in pa­tients with Can­di­da in­fec­tions.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER